Defining the hypoxic target volume based on positron emission tomography for image guided radiotherapy – the influence of the choice of the reference region and conversion function

Abstract Background: Hypoxia imaged by positron emission tomography (PET) is a potential target for optimization in radiotherapy. However, the implementation of this approach with respect to the conversion of intensities in the images into oxygenation and radiosensitivity maps is not straightforward. This study investigated the feasibility of applying two conversion approaches previously derived for 18F-labeled fluoromisonidazole (18F-FMISO)-PET images for the hypoxia tracer 18F-flortanidazole (18F-HX4). Material and methods: Ten non-small-cell lung cancer patients imaged with 18F-HX4 before the start of radiotherapy were considered in this study. PET image uptake was normalized to a well-oxygenated reference region and subsequently linear and non-linear conversions were used to determine tissue oxygenations maps. These were subsequently used to delineate hypoxic volumes based partial oxygen pressure (pO2) thresholds. The results were compared to hypoxic volumes segmented using a tissue-to-background ratio of 1.4 for 18F-HX4 uptake. Results: While the linear conversion function was not found to result in realistic oxygenation maps, the non-linear function resulted in reasonably sized sub-volumes in good agreement with uptake-based segmented volumes for a limited range of pO2 thresholds. However, the pO2 values corresponding to this range were significantly higher than what is normally considered as hypoxia. The similarity in size, shape, and relative location between uptake-based sub-volumes and volumes based on the conversion to pO2 suggests that the relationship between uptake and pO2 is similar for 18F-FMISO and 18F-HX4, but that the model parameters need to be adjusted for the latter. Conclusions: A non-linear conversion function between uptake and oxygen partial pressure for 18F-FMISO-PET could be applied to 18F-HX4 images to delineate hypoxic sub-volumes of similar size, shape, and relative location as based directly on the uptake. In order to apply the model for e.g., dose-painting, new parameters need to be derived for the accurate calculation of dose-modifying factors for this tracer.

[1]  P. Lambin,et al.  Evaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  Philippe Lambin,et al.  PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  P. Lambin,et al.  Imaging of tumour hypoxia and metabolism in patients with head and neck squamous cell carcinoma , 2015, Acta oncologica.

[4]  W. V. van Elmpt,et al.  Comparison of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia – a simulation study , 2015, Acta oncologica.

[5]  P. Lambin,et al.  Repeatability of hypoxia PET imaging using [18F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  A. Windhorst,et al.  Feasibility and repeatability of PET with the hypoxia tracer [(18)F]HX4 in oesophageal and pancreatic cancer. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  Kenneth A Krohn,et al.  F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy. , 2015, Seminars in nuclear medicine.

[8]  P. Lambin,et al.  A comparative study of the hypoxia PET tracers [¹⁸F]HX4, [¹⁸F]FAZA, and [¹⁸F]FMISO in a preclinical tumor model. , 2015, International journal of radiation oncology, biology, physics.

[9]  P. Lambin,et al.  In Vivo Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [18F]HX4 and [18F]FDG-PET/CT Imaging , 2014, Clinical Cancer Research.

[10]  Hanwen Zhang,et al.  A Comparison of the Imaging Characteristics and Microregional Distribution of 4 Hypoxia PET Tracers , 2014, The Journal of Nuclear Medicine.

[11]  V. Khoo,et al.  Hypoxia-targeted radiotherapy dose painting for head and neck cancer using 18F-FMISO PET: A biological modeling study , 2013, Acta oncologica.

[12]  P. Lambin,et al.  Hypoxia imaging with [¹⁸F]HX4 PET in NSCLC patients: defining optimal imaging parameters. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  Yihui Guan,et al.  18F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with 18F-FMISO , 2012, Nuclear medicine communications.

[14]  Anders Brahme,et al.  Dose prescription and treatment planning based on FMISO-PET hypoxia , 2012, Acta oncologica.

[15]  Philippe Lambin,et al.  Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging , 2011, Proceedings of the National Academy of Sciences.

[16]  Vincent Gregoire,et al.  Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. , 2011, Seminars in radiation oncology.

[17]  M. Dewhirst,et al.  Molecular Imaging of Hypoxia , 2011, The Journal of Nuclear Medicine.

[18]  Philippe Lambin,et al.  PET imaging of hypoxia using [18F]HX4: a phase I trial , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  Matthias Reimold,et al.  Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  T K Lewellen,et al.  Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.

[21]  S. Dische Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy. , 1985, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  J. D. Chapman,et al.  A marker for hypoxic cells in tumours with potential clinical applicability. , 1981, British Journal of Cancer.

[23]  Chapman Jd,et al.  Hypoxic sensitizers--implications for radiation therapy. , 1979 .

[24]  P. Lambin,et al.  A Comparative Study of the Hypoxia PET Tracers ( 18 F)HX4, ( 18 F)FAZA, and ( 18 F)FMISO in a , 2015 .

[25]  Anders Brahme,et al.  Quantifying tumour hypoxia by PET imaging--a theoretical analysis. , 2009, Advances in experimental medicine and biology.

[26]  K L Lindsley,et al.  Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. , 1995, International journal of radiation oncology, biology, physics.

[27]  J. Chapman Hypoxic sensitizers--implications for radiation therapy. , 1979, The New England journal of medicine.